The mechanisms of atrial fibrillation in hyperthyroidism by unknown
BioMed CentralThyroid Research
ssOpen AcceReview
The mechanisms of atrial fibrillation in hyperthyroidism
Agata Bielecka-Dabrowa1, Dimitri P Mikhailidis2, Jacek Rysz3 and 
Maciej Banach*1
Address: 1Department of Hypertension, Medical University of Lodz, Lodz, Poland, 2Department of Clinical Biochemistry, Royal Free Campus, 
University College Medical School, University College London, London, UK and 3Department of Nephrology, Hypertension and Family Medicine, 
Medical University of Lodz, Lodz, Poland
Email: Agata Bielecka-Dabrowa - agatbiel7@poczta.onet.pl; Dimitri P Mikhailidis - mikhailidis@aol.com; 
Jacek Rysz - jacek.rysz@skwam.lodz.pl; Maciej Banach* - maciejbanach@aol.co.uk
* Corresponding author    
Abstract
Atrial fibrillation (AF) is a complex condition with several possible contributing factors. The rapid
and irregular heartbeat produced by AF increases the risk of blood clot formation inside the heart.
These clots may eventually become dislodged, causing embolism, stroke and other disorders. AF
occurs in up to 15% of patients with hyperthyroidism compared to 4% of people in the general
population and is more common in men and in patients with triiodothyronine (T3) toxicosis. The
incidence of AF increases with advancing age. Also, subclinical hyperthyroidism is a risk factor
associated with a 3-fold increase in development of AF. Thyrotoxicosis exerts marked influences
on electrical impulse generation (chronotropic effect) and conduction (dromotropic effect).
Several potential mechanisms could be invoked for the effect of thyroid hormones on AF risk,
including elevation of left atrial pressure secondary to increased left ventricular mass and impaired
ventricular relaxation, ischemia resulting from increased resting heart rate, and increased atrial
eopic activity. Reentry has been postulated as one of the main mechanisms leading to AF. AF is
more likely if effective refractory periods are short and conduction is slow. Hyperthyroidism is
associated with shortening of action potential duration which may also contribute to AF.
Introduction
Atrial fibrillation (AF) is a common dysrrhythmia repre-
senting an independent risk factor for cardiovascular
events [1]. The rapid and irregular heartbeat produced by
AF increases the risk of blood clot formation inside the
heart. These clots may eventually become dislodged, caus-
ing embolism, stroke and other disorders [1,2]. AF is a
complex disease with several possible mechanisms. Stud-
ies indicate that arrhythmogenic foci within the thoracic
veins can be AF initiators [2]. Once initiated, AF alters
atrial electrical and structural properties in a way that pro-
motes its own maintenance; this increases the risk of
recurrence and may alter the response to antiarrhythmic
drugs [2,3]. AF may occur in patients with a variety of car-
diovascular or chronic diseases as well as in normal sub-
jects. It is the most common cardiac complication of
hyperthyroidism [3]. AF in thyrotoxicosis is associated
with significant mortality and morbidity resulting from
embolic events [3]. The risk factors for AF in patients with
hyperthyroidism (age, male sex, ischemic heart disease,
congestive heart failure and valvular heart disease) are
similar to those in the general population [4]. AF occurs
in up to 15% of patients with hyperthyroidism [5] com-
pared with 4% incidence in the general population [6]
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dothyronine (T3) toxicosis [3]. Also, subclinical hyperthy-
roidism is a risk factor that is associated with a 3-fold
increase in risk of developing AF [5]. AF incidence
increases with advancing age. Although it is rare in
patients under 40 years of age, 25% to 40% of hyperthy-
roid individuals over the age of 60 experience AF, possibly
reflecting an age-related reduction in threshold for acquir-
ing this arrhythmia. Of hyperthyroid patients older than
60 years, 25% had AF compared with 5% prevalence in
patients younger than 60 years [7]. Patients with toxic
nodular goiter also showed, because of their age, an
increased prevalence of AF versus younger patients with
Graves' disease (43% vs 10%, respectively). Also, analysis
of rhythm disorders in 219 patients with hyperthyroidism
[8] showed an age-dependent distribution of AF and sinus
node dysfunctions.
In a large study [9] of patients with new-onset AF, less
than 1% of AF incidence was caused by overt hyperthy-
roidism. Therefore, although serum thyroid-stimulating
hormone (TSH) is measured in all patients with new-
onset AF to rule out thyroid disease, this association is
uncommon in the absence of additional symptoms and
signs of hyperthyroidism.
Treatment of hyperthyroidism results in conversion to
sinus rhythm in up to two-thirds of patients. In a prospec-
tive trial, the arrhythmia profile was analyzed in hyperthy-
roid patients, before, during, and after antithyroid therapy
[10]. The number of patients with atrial premature com-
plexes was elevated compared with controls (88 vs 30%)
and decreased markedly after treatment. As with other
causes of AF, the main determinant of reversion seems to
be the duration of AF [11]. Patients who had been in AF
for more than 1 year and those who were in advanced age
were likely to need intervention in the long run, probably
reflecting the coexistence of ischaemic heart disease in
these hyperthyroid patients with AF [12]. No association
of subclinical hypothyroidism with AF has been found
[5,13-15].
The 'hypothalamic -pituitary -thyroid axis'
Thyroxine (T4) and triiodothyronine (T3) are tyrosine-
based hormones produced by the thyroid gland. The
major form of thyroid hormone in the blood is thyroxine
(T4). The ratio of T4 to T3 in the blood is roughly 20 to 1.
Thyroxine is converted to the active T3 form (3 to 4 times
more potent than T4) by deiodinases. TSH stimulates the
thyroid gland to secrete the thyroid hormones. TSH pro-
duction is controlled by thyrotropin releasing hormone
(TRH), which is synthesised in the hypothalamus and
transported to the anterior pituitary gland via the superior
hypophyseal artery, where it increases TSH production
and release. Somatostatin is also produced by the hypoth-
alamus, and has an opposite effect on the pituitary pro-
duction of TSH, decreasing or inhibiting its release.
The levels of T3 and T4 in the blood have a feedback effect
on the pituitary release of TSH. When the levels of T3 and
T4 are low, the production of TSH is increased, and con-
versely, when levels of T3 and T4 are high, then TSH pro-
duction is decreased. This effect creates a regulatory
negative feedback loop.
Subclinical hyperthyroidism as a risk for AF
Subclinical hyperthyroidism is defined as low serum thy-
rotropin concentration in an asymptomatic patient with
normal serum T3 and T4 concentration [16]. The preva-
lence among adults is up to 12% and increases with age
[16-18]. Subclinical hyperthyroidism can occur as a result
of thyroid pathology such as Graves' disease, multinodu-
lar goiter, or autonomous toxic nodules or may be exoge-
nous due to thyroxine therapy [18]. Subclinical
hyperthyroidism may be a consequence of L-thyroxine (L-
T4) therapy [19]. The abnormalities found in patients with
subclinical hyperthyroidism are increased heart rate and
prevalence of supraventricular arrhythmias and enhanced
left ventricular mass (LVM) due to concentric remodeling
[19]. The increase in LVM is associated with slightly
enhanced systolic function and almost always with
impaired diastolic function due to slowed myocardial
relaxation [19-23]. It rarely corresponds to actual left ven-
tricle hypertrophy and is related to the duration of sub-
clinical hyperthyroidism rather than to circulating thyroid
hormone levels. It is assumed that these changes develop
in response to a chronic hemodynamic overload due to
the mild hyperkinetic cardiovascular state [24].
It is reported that a low serum thyrotropin concentration
in an asymptomatic person with normal serum thyroid
hormone concentrations can be an independent risk fac-
tor for developing AF [24,25].
A retrospective cross-sectional study [14] compared AF
prevalence in 1338 subjects with overt or subclinical
hyperthyroidism due to autonomous thyroid nodules or
Graves disease with AF prevalence in a control group of
22300 subjects admitted to a hospital. The prevalence of
AF was 13.8% in patients with overt hyperthyroidism,
12.7% in those with subclinical hyperthyroidism, and
2.3% in euthyroid controls. The relative risk (RR) of AF in
those with subclinical hyperthyroidism was 5.2 (95% CI,
2.1–8.7) compared with controls. Thus, a low serum TSH
concentration is associated with a more than 5-fold higher
likelihood for the presence of AF. There was no significant
difference between the risk of AF in patients with subclin-
ical and overt hyperthyroidism [14]. In another study [5]
in patients older than 60 years, subjects with low thyrotro-
pin (<0.1 mU/L) had a 28% incidence of AF comparedPage 2 of 7
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lower serum thyrotropin concentration (0.1 to 0.4 mU/L)
also had a higher risk of AF than those with a normal thy-
rotropin concentration (RR 1.6; p = 0.05). There was no
significant difference in AF occurrence between overt and
subclinical hyperthyroidism [5].
Similar findings have been reported by Cappola et al. [13]
investigating incident AF in 3233 US community-dwell-
ing subjects 65 years or older. After exclusion of those
with preexisting AF, those with subclinical hyperthy-
roidism (1.6% of the cohort) had a greater incidence of AF
compared with those with normal thyroid function over a
period of 12 years [adjusted hazards ratio (HR), 1.98;
95% CI, 1.29–3.03]. In the study of Kwon et al. [25] the
significance of serum TSH in the euthyroid patient with
AF whose serum level of T3, T4, free T4 (fT4), and were
absolutely within normal range was assessed. The cutoff
serum TSH value that distinguished between paroxysmal
and chronic AF was 1.568 U/mL (76% predictive power).
There was a significantly lower serum TSH in paroxysmal
AF in all age groups (p < 0.05). The authors suggest that
serum TSH below the serum concentration of 1.5 U/mL
can be a risk factor for developing AF.
Overt hyperthyroidism and AF risk
In a large study including more than 23000 persons, AF
was present in 513 subjects (2.3%) in the group with nor-
mal values for serum TSH, and in 78 (12.7%) and 100
(13.8%) in the groups with subclinical and overt hyper-
thyroidism, respectively [14].
In the study of Gammage et al. [26], serum fT4 was an
independent predictor of the presence of AF in the cohort
as a whole, and this association was sustained after exclu-
sion of those with overt thyroid dysfunction. Further-
more, when the analysis was further restricted to those
classified as euthyroid (with normal serum TSH concen-
tration), the relationship between serum fT4 and AF was
still evident.
In the Rotterdam Study [27] patients with high normal
serum fT4 concentrations also had a higher risk of AF. The
multivariate adjusted level of fT4 showed a graded associ-
ation with the risk of AF (HR, 1.62; 95% CI, 0.84–3.14,
highest versus lowest quartile; p for trend, 0.06).
Effects of thyroid hormones on the 
cardiovascular system
Overt hyperthyroidism induces a hyperdynamic cardio-
vascular state (high cardiac output with low systemic vas-
cular resistance), which is associated with a faster heart
rate, enhanced left ventricular systolic and diastolic func-
tion, and increased prevalence of supraventricular tach-
yarrhythmias [28].
Thyroid hormones may exert both genomic and nong-
enomic effects on cardiac myocytes [28]. The genomic
effects of thyroid hormones are mediated by transcrip-
tional activation or repression of specific target genes that
encode both structural and functional proteins [29].
Triiodothyronine (T3) is the biologically active thyroid
hormone that gets into the cardiomyocyte through spe-
cific transport proteins located within the cell membrane,
and which then interacts with specific transcriptional acti-
vators (nuclear receptor α-1) or repressors (nuclear recep-
tor α-2) [30]. Occupancy of these receptors by T3, in
combination with recruited cofactors, allows the thyroid
hormone-receptor complex to bind (nuclear receptor α-1)
or release (nuclear receptor α-2) specific sequences of
DNA (thyroid-responsive elements) that, in turn, by act-
ing as cis- or trans-regulators, modify the rate of transcrip-
tion of specific target genes [28,31].
Severely hyperthyroid patients can show signs of conges-
tive heart failure in the absence of prior cardiac pathology
[32]. Cardiac manifestations in hyperthyroid patients can
be the result of thyrotoxicosis itself, underlying heart dis-
ease that decompensates due to hyperthyroidism-induced
increased demand on the heart, or increased occurrence of
specific cardiac abnormalities [32]. Hyperthyroid patients
frequently complain of dyspnea on exertion even in the
absence of cardiac failure [33]. Because hyperthyroidism
leads to a weakening of skeletal and intercostal muscles,
dyspnea may be related more to a weakness of respiratory
muscles than to cardiac abnormalities themselves [33-38].
Several lines of evidence suggest that some abnormalities
of cardiac function in patients with thyroid dysfunction
directly reflect the effects of thyroid hormones on cal-
cium-activated ATPase and phospholamban, which are
involved primarily in the regulation of systodiastolic cal-
cium concentrations in cardiomyocytes [34]. Sarcoplas-
mic reticulum calcium-activated ATPase is responsible for
the rate of calcium reuptake into the lumen of the sarco-
plasmic reticulum during diastole that, in turn, is a major
determinant of the velocity of myocardial relaxation after
contraction [29,34]. It has been extensively demonstrated
that thyroid hormone upregulates expression of the sarco-
plasmic reticulum calcium-activated ATPase and down-
regulates expression of phospholamban, thereby
enhancing myocardial relaxation [29,34]. The improved
calcium reuptake during diastole may favorably affect
myocardial contractility [34]. Some evidence indicates
that thyroid hormones promote the acute phosphoryla-
tion of phospholamban and that this action attenuates
the inhibitory effect of phospholamban on sarcoplasmic
reticulum calcium-activated ATPase [35]. Interestingly,
the fact that this process is mediated at least in part by the
activation of intracellular kinase pathways involved in sig-
nal transduction of adrenaline [35] may help to explainPage 3 of 7
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thyroid hormone and those promoted by the adrenergic
system [36]. The circadian rhythm of heart rate is main-
tained in thyrotoxicosis, although heart rate variability is
significantly increased, supporting the view that normal
adrenergic responsiveness persists in thyrotoxicosis [37].
Electrophysiological mechanism of AF in 
hyperthyroidism
Several potential mechanisms could be invoked for the
effect of thyroid hormones on AF risk, including elevation
of left atrial pressure secondary to increased LVM and
impaired ventricular relaxation [28], ischemia resulting
from raised resting heart rate, and increased atrial ectopic
activity [39]. Studies using an isolated heart model found
that hearts from animals with experimental thyrotoxicosis
show increased heart rates and shorter mean effective
refractory periods than hearts from euthyroid animals
[37]. In patients with hyperthyroidism increased heart
rate and a decreased turbulence slope (TS) (TS quantifies
the rate of sinus slowing that follows the sinus tachycar-
dia) consistent with decreased vagal tone were observed
[40].
Hyperthyroidism is associated with an increased
supraventricular ectopic activity in patients with normal
hearts [40]. Wustmann et al. [40] assessed the activity of
abnormal supraventricular electrical depolarizations at
baseline and follow-up after normalization of serum TSH
levels. The abnormal premature supraventricular depo-
larization, the number of episodes of supraventricular
tachycardia and nonsustained supraventricular tachycar-
dia decreased significantly (p = 0.003, p < 0.0001, p =
0.01) after normalization of serum thyrotropin levels. The
activation of arrhythmogenic foci by elevated thyroid hor-
mones may be an important causal link between hyper-
thyroidism and AF.
Heart rate effects are mediated by T3-based increases in
systolic depolarization and diastolic repolarization and
decrease in the action potential duration and the refrac-
tion period of the atrial myocardium, as well as the atrial/
ventricular nodal refraction period. T3 induces electro-
physiological changes partly due to its effects on sodium
pump density and enhancement of Na+ and K+ permeabil-
ity [41]. Expression of the L-type calcium channel 1D,
which also serves as an important pacemaker function, is
also increased by T3.
In vitro studies found that T3 decreases the duration of the
repolarization phase of the membrane action potential
and increases the rate of the diastolic repolarization and
therefore the rate of contraction [42-44].
Reentry has been postulated as one of the main mecha-
nisms leading to AF [45-47]. Multicircuit wave fronts that
are generated in the atrium could disturb normal sinus
rhythm and set up a fibrillatory rhythm [45-47]. Accord-
ing to wavelength concepts, AF is more likely if effective
refractory periods are short and conduction is slow [47].
Hyperthyroidism is associated with shortening of action
potential duration [47]. Action potential duration (APD)
determines the refractory period and is therefore a key
determinant of the likelihood of reentry [46,47]. It has
been reported that the properties of electrophysiological
repolarization are not homogeneous within the 2 atria. Li
et al. [48] determined that the higher density of the rapid
delayed rectifier current (IKr) in left atrial myocytes con-
tributed to the shorter effective refractory period and APD
in canine left atrium.
In several studies, changes have been observed in the
expression of various ion channel mRNAs in both atria
[49,50] and ventricles [49,51,52] under hyperthyroid con-
ditions.
Watanabe et al. [50] revealed a remarkable increase in the
ultrarapid delayed rectifier potassium currents in hyper-
thyroid compared with euthyroid myocytes, whereas the
transient outward potassium currents were unchanged. L-
type calcium currents were decreased in hyperthyroid
compared to euthyroid myocytes. T3 increased the out-
ward currents and decreased the inward currents, resulting
in shortened APD.
Between the atrium and ventricle of the adult rat heart, the
responses of gene expression of voltage-gated potassium
channels to T3 were different and the variability of
responses may explain cardiac manifestations of hyper-
thyroidism [49].
Hu et al. [53] assessed the electrophysiological changes
that occur in left and right atria with hyperthyroidism, the
patch-clamp technique was used to compare APD and
whole cell currents in myocytes from left and right atria in
both control and hyperthyroid mice. The RNAse protec-
tion assay and Western blotting were used to evaluate the
mRNA and protein levels of α-subunits constituting the
corresponding ion channel pore in the atrium. In hyper-
thyroid mice shortened APD and increased delayed recti-
fier currents (both the ultra-rapid delayed rectifier K+
conductance -IKur and the sustained delayed rectifier K+
conductance -Iss) in atrial myocytes were observed. Mes-
senger RNA and protein expression levels of the main
potential pore-forming subunits for these 2 currents,
Kv1.5 and Kv2.1, were also higher in both atria in this
group. It is likely that increased Kv1.5 and Kv2.1 expres-
sion reflects increased channel synthesis and at least par-
tially contributes to the higher density of IKur and IssPage 4 of 7
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between alteration of Kv1.5 protein but not Kv2.1 expres-
sion and mRNA level was observed in hyperthyroid atria.
This suggests that thyroid hormones may regulate Kv2.1
expression at a posttranscriptional level. The influence of
hyperthyroidism on APD and delayed rectifier K+ currents
was more prominent in right than in left atrium, which
minimized the interatrial APD difference. Several factors
such as differential pressure stress force, autonomic nerve
innervation, or different transcriptional factor distribu-
tion between the 2 atria may play a role in this process.
The overall shortening of action potential duration in
hyperthyroid atria, which is reflective of a shorter effective
refractory period, would facilitate the occurrence of reen-
try. Contrary to the normal interatrial APD difference that
is important for synchronizing contraction of both atria
(due to the physiological origination of sinus rhythm on
the right side), the diminished interatrial APD difference
may enhance the spreading of ectopic activity originating
mostly from left atrium to the whole atria. Therefore, it is
possible that the diminished interatrial APD would facili-
tate the generalization of irregular activities in a hyperthy-
roid state and provide the substrate for atrial arrhythmias
such as AF [53]. Pulmonary veins are known to initiate
paroxysmal AF [54]. Increased automaticity may also play
a role in the arrhythmogenesis in hyperthyroid pulmo-
nary veins [54]. Research using rabbit pulmonary vein car-
diomyocytes has shown that thyroid hormones decrease
the APD in pulmonary vein cardiomyocytes which can
decrease the refractory interval and facilitate the genesis of
reentrant circuits [54,55]. Incubation with thyroid hor-
mones also increased spontaneous activity in pulmonary
vein cardiomyocytes similar to its effect on sinoatrial node
cells. Previous studies in humans or in isolated canine
pulmonary vein tissues also have demonstrated that trig-
gered activities may underlie the arrhythmogenic activity
of pulmonary veins [55,56].
Thyroid hormones induced the occurrence of delayed
after-depolarization (DAD) in beating and non-beating
pulmonary vein cardiomyocytes. Transient inward cur-
rents have been suggested to play an important role in the
genesis of DAD [57,58]. Tseng and Wit [57] showed that
transient inward currents may play a role in the triggered
activity of atrial cells in the coronary sinus. In the studies
by Chen et al. [54-56] both the beating and non-beating
hyperthyroid pulmonary vein cardiomyocytes had greater
transient inward currents after being incubated with thy-
roid hormones, which may underlie the high incidence of
DAD in these cells. In the beating cardiomyocytes, the
incidence of early depolarization (EAD), defined as the
generation of oscillatory potentials at depolarized levels,
was also increased after incubation with thyroid hor-
mones [54-56].
These findings suggest that thyroid hormones may induce
the occurrence of paroxysmal AF through the increase of
triggered activity in pulmonary veins. Thyroid hormones
have little effects on the triggered activity of atrial cells,
which suggests that these cells have different responses to
thyroid hormone.
Is it necessary to screen for thyroid function?
Regarding the high incidence of AF in older patients with
thyrotoxicosis, it is important to detect thyroid dysfunc-
tion in subjects over 60 year of age. Once euthyroidism is
restored, all patients who revert spontaneously to sinus
rhythm (~60%) do so within 4 months of becoming
euthyroid [59]. The finding that subclinical hyperthy-
roidism detected as a result of screening is associated with
AF contributes to the debate about the value of screening
at-risk populations. This debate needs to be informed by
evidence from trials investigating whether treatment pre-
vents or reverses AF [26].
Screening thyroid function tests to exclude occult hyper-
thyroidism as the cause of AF should include total or free
T3 and T4 and high sensitivity TSH measurements.
Triiodothyronine concentration may be within the refer-
ence range in patients who are hyperthyroid and have AF
[59]. The measurement of T4 alone can be also unsatisfac-
tory, especially in patients with thyrotoxicosis, particu-
larly if they have been treated for hyperthyroidism, with a
nodular goitre or an autonomous thyroid nodule [60].
The TSH-producing cells of the anterior pituitary are sen-
sitive to minor changes in circulating thyroid hormones
and absent or subnormal TSH concentrations may be
found in hyperthyroid patients in whom the T3 and T4
concentrations are higher than normal for the individual
but within or at the upper end of the accepted reference
range.
An electrocardiogram may be helpful in identifying hyper-
thyroid subjects at risk for developing AF. Maximum P
wave duration and P wave dispersion were higher in both
subclinical and overt hyperthyroidism. P maximum and P
wave dispersion were significant predictors of paroxysmal
AF [60-62].
Conclusions
Several potential mechanisms could be invoked for the
effect of thyroid hormones on AF risk and this association
is well documented in the literature.
It is especially important to detect thyroid dysfunction in
all subjects over 60 year of age, as once euthyroidism is
restored all patients who revert spontaneously to sinus
rhythm do so within 4 months of becoming euthyroid.
The finding that subclinical hyperthyroidism detected as aPage 5 of 7
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debate about the value of screening at-risk populations.
This debate still needs to be informed by evidence from
trials investigating whether treatment prevents or reverses
AF [59,60].
Nevertheless in all patients with AF, before implementing
pharmacological or invasive treatment, we should
remember the association with thyroid diseases, as sinus
rhythm is often restored after normal levels of thyroid
hormones are achieved [61,62].
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